Updates to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection (October 11, 2022)
Posted October 12, 2022Updates to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has made revisions in the following sections of the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection to address U.S. Food and Drug Administration approval of the dispersible tablet formulation of the fixed-dose combination abacavir/dolutegravir/lamivudine (Triumeq PD) for use in children weighing 10 kg to 25 kg and the long-acting injectable cabotegravir and rilpivirine (Cabenuva) for use in children and adolescents aged ≥12 years and weighing ≥35 kg.
- What to Start: Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children
- What Not to Start: Regimens Not Recommended for Use in Antiretroviral-Naive Children
- Management of Children Receiving Antiretroviral Therapy: Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy
- Drug sections: Abacavir, Lamivudine, Dolutegravir, Cabotegravir, and Rilpivirine
For a complete list of recent updates, please see What’s New in the Guidelines. To view or download the guidelines, go to the Pediatric ARV Guidelines section of Clinical Info’s website. The guidelines tables and recommendations also can be downloaded as separate PDF files.
Clinical Info welcomes your feedback on the latest revisions to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Please send your comments with the subject line “Pediatric ARV Guidelines” to HIVinfo@NIH.gov by November 1, 2022.
